Double-blind donepezil-placebo crossover augmentation study of atypical antipsychotics in chronic, stable schizophrenia: A pilot study

Schizophrenia Research

Volumn 93, Issue 1-3, 2007, Pages 131-135

  Risch, S Craig ^a   Horner, Michael D ^b,c   McGurk, Susan R ^d   Palecko, Simmy ^a   Markowitz, John S ^c   Nahas, Ziad ^c   DeVane, C Lindsay ^c  

^a UNIVERSITY OF CALIFORNIA   (United States)

^b RALPH H JOHNSON VA MEDICAL CENTER   (United States)

^c MEDICAL UNIVERSITY OF SOUTH CAROLINA   (United States)

^d DARTMOUTH MEDICAL SCHOOL   (United States)

Author keywords

Cholinesterase Inhibitors; Pharmacological Augmentation; Schizophrenia

Indexed keywords

CHOLINESTERASE INHIBITOR; CLOZAPINE; DONEPEZIL; OLANZAPINE; PLACEBO; RISPERIDONE;

ADULT; ARTICLE; CLINICAL ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; CROSSOVER PROCEDURE; DOUBLE BLIND PROCEDURE; DRUG DOSE TITRATION; HUMAN; OUTCOME ASSESSMENT; PILOT STUDY; POSITIVE AND NEGATIVE SYNDROME SCALE; PRIORITY JOURNAL; SCHIZOPHRENIA; SCORING SYSTEM;

ADULT; ANTIPSYCHOTIC AGENTS; BENZODIAZEPINES; CHOLINESTERASE INHIBITORS; CLOZAPINE; CROSS-OVER STUDIES; DOUBLE-BLIND METHOD; DRUG THERAPY, COMBINATION; FEMALE; HUMANS; INDANS; MALE; MIDDLE AGED; NOOTROPIC AGENTS; PIPERIDINES; PSYCHIATRIC STATUS RATING SCALES; PSYCHOTIC DISORDERS; RISPERIDONE; SCHIZOPHRENIA; SCHIZOPHRENIC PSYCHOLOGY; TREATMENT OUTCOME;

EID: 34249317238     PISSN: 09209964     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.schres.2007.01.001     Document Type: Article

References (36)

1. Adler L.E., Olincy A., Waldo M., Harris J.G., Griffith J., Stevens K., Flach K., Nagamoto H., Bickford P., Leonard S., and Freeman R. Schizophrenia, sensory gating and nicotinic receptors. Schizophrenia Bulletin 24 2 (1998) 189-202
2. Allen T.B., and McEvoy J.P. Galantamine for treatment-resistant schizophrenia. American Journal of Psychiatry 159 (2002) 1244-1245
3. Barnes T.R.E. A rating scale for drug-induced akathisia. British Journal of Psychiatry 154 (1989) 672-676
4. Breese C.R., Lee M.J., Adams C.E., Sullivan B., Logel J., Gillen K.M., Marks M.J., Collins A.C., and Leonard S. Abnormal regulation of high affinity nicotinic receptors in subjects with schizophrenia. Neuropsychopharmacology 23 4 (2000) 351-364
5. Buchanan R.W., Summerfelt A., Tek C., and Gold J. An open-labeled trial of adjunctive donepezil for cognitive impairments in patients with schizophrenia. Schizophrenia Research 59 (2003) 29-33
6. Cohen J. Statistical power analysis for the behavioral science. 2nd ed. (1988), Lawrence Earlbaum Associates, Hillsdale, NJ
7. Crook J.M., Tomaskovic-Crook E., Copolov D.L., and Dean B. Decreased muscarinic receptor binding in subjects with schizophrenia: a study of the human hippocampal formation. Biological Psychiatry 48 5 (2000) 381-388
8. Cummings J.L. Cholinesterase inhibitors: a new class of psychotropic compounds. American Journal of Psychiatry 157 1 (2000) 4-15
9. Erickson S.K., Schwarzkopf S.B., Palumbo D., Badgley-Fleeman J., Smirnow A.M., and Light G.A. Efficacy and tolerability of low-dose donepezil in schizophrenia. Clinical Neuropharmacology 28 (2005) 179-184
10. Davidson M., Harvey P., Welsh K.A., Powchick P., Putnam K.M., and Mohs R.C. Cognitive functioning in late-life schizophrenia: a comparison of elderly schizophrenias patients and patients with Alzheimer's disease. American Journal of Psychiatry 153 (1996) 1274-1279
11. Freedman R., Coon H., Myles-Worsely M., Orr-Urtreger A., Olincy A., Davis A., Polymeropoulos M., Holik J., Hoff M., Rosenthal J., Waldo M.C., Reimher F., Wender P., Yaw J., Young D.A., Greese C.R., Adams C., Paterson D., Adler L., Kruglyak L., Leonard S., and Byerley W. Linkage of a neuropysiological deficit in schizophrenia to a chromosome 15 locus. Proceedings of the National Academy of Sciences of the United States of America 94 (1997) 587-592
12. Friedman J.L., Adler D.N., Howanitz E., Harvey P.D., Brenner G., Temporini H., White L., Parrella M., and Davis K.L. A double blind placebo controlled trial of donepezil adjunctive treatment to risperidone for the cognitive impairment of schizophrenia. Biological Psychiatry 51 (2002) 349-357
13. Goldberg T.E., Weinberger D., Berman K.E., Piskin N.I.H., and Podd M.H. Further evidence for dementia of the prefrontal type in schizophrenia? A controlled study of the wisconsin card sorting test. Archives of General Psychiatry 44 (1987) 1008-1014
14. Green M.F., Kern R.S., et al. Neurocognitive deficits and functional outcome in schizophrenia: are we measuring the "right stuff"?. Schizophrenia Bulletin 26 (2000) 119-136
15. Hans S.L., Marcus J., Nuechterlein K.H., Asarnow R.F., Styr B., and Auerbach J.G. Neurobehavioral deficits at adolescence in children at risk for schizophrenia. The Jerusalem Infant Development Study. Archives of General Psychiatry 56 (1999) 741-748
16. Heaton R., Paulsen J.S., McAdams L.A., Kuck J., Zisook S., Braff D., Harris M.J., and Jeste D.V. Neuropsychological deficits in schizophrenias: relationship to age, chronicity and dementia. Archives of General Psychiatry 51 6 (1994) 469-476
17. Holt D.J., Bachus S.E., Hyde T.M., Wittie M., Herman M.M., Vangel M., Saper C.B., and Kleinman J.E. Reduced density of cholinergic interneurons in the ventral striatum in schizophrenia: an in situ hybridization study. Biological Psychiatry 58 (2005) 408-416
18. Howard A.K., Thornton A.E., Altman S., and Honer W.G. Donepezil for memory dysfunction in schizophrenia. Journal of Psychopharmacology 16 (2002) 267-270
19. Hughes C.P., Berg L., Danziger W.L., Coben L.A., and Martin R.L. A new clinical scale for the staging of dementia. British Journal of Psychiatry 14 (1982) 566-572
20. Kay S.R., Fiszbein A., and Opler L.A. The positive and negative syndrome scale (PANSS) for schizophrenia. Schizophrenia Bulletin 13 2 (1987) 261-276
21. Lane R.D., Glazer W.M., Hansen T.E., Berman W.H., and Kramer S.L. Assessment of tardive dyskinesia using the abnormal involuntary movements scale. The Journal of Nervous and Mental Disease 173 (1985) 353-357
22. Lawrence A.D., and Sahakian B.J. Alzheimer disease, attention, and the cholinergic system. Alzheimer Disease and Associated Disorders 9 Supplement 2 (1995) 43-49
23. Lenzi A., Maltinti E., Poggi E., Fabrizio L., and Coli E. Effects of rivastigmine of cognitive function and quality of life in patients with schizophrenia. Clinical Neuropharmacology 26 (2003) 317-321
24. MacEwan G.W., Ehmann T.S., Khanbhai I., and Wrixon C. Donepezil in schizophrenia-is it helpful? An experimental design case study. Acta Psychiatrica Scandinavica 104 6 (2001) 469-472
25. Maelicke A., and Albuquerque E.X. Allosteric modulation of nicotinic acetylcholine receptors as a treatment strategy for Alzheimer's disease. European Journal of Pharmacology 393 (2000) 165-170
26. Mendelsohn E., Rosenthal M., Bohiri Y., Weber E., Kotle M., and Strous R.D. Rivastigmine augmentation in the management of chronic schizophrenia with comorbid dementia: an open-label study investigating effects on cognition, behaviour and activities of daily living. International Clinical Psychopharmacology 19 (2004) 319-324
27. Miller A.L. Combination treatments for schizophrenia. CNS Spectrums 9 9 (2004) 19-23
28. Mohamed S., Paulsen J.S., O'Leary D., Arndt S., and Andreasen N. Generalized cognitive deficits in schizophrenia. Archives of General Psychiatry 56 (1999) 749-754
29. Powchick P., Davidson M., Haroutunian V., Gabriel S.M., Purohit P., Perl D.P., Harvey P.D., and Davis K.L. Postmortem studies in schizophrenia. Schizophrenia Bulletin 24 3 (1998) 325-341
30. Risch S.C., McGurk S., Horner M.D., Nahas Z., Owens S.D., Molloy M., Gilliard C.E., Christie S., Markowitz J.S., DeVane C.L., Mintzer J., and George M.S. A double-blind placebo controlled case study of the use of donepezil to improve cognition in a schizoaffective disorder patient: fMRI correlates. Neurocase 7 (2001) 105-110
31. Risch S.C., Horner M.D., McGurk S., Palecko S., Markowitz J.S., Nahas Z., and DeVane C.L. Donepezil effects on mood in patients with schizophrenia and schizoaffective disorder. International Journal of Neuropsychopharmacology 9 (2005) 1-3
32. Rosse R.B., and Deusch S.I. Adjuvant galantamine administration improves negative symptoms in a patient with treatment-refractory schizophrenia. Clinical Neuropharmacology 25 (2002) 272-275
33. Schubert M.H., Young K., and Hicks P.B. Galantamine improves cognition in schizophrenic patients stabilized on risperidone. Biological Psychiatry 60 6 (2006) 530-533
34. Simpson G.N., and Angus J.W.S. A rating scale for extrapyramidal side effects. Acta Psychiatrica Scandinavica 212 suppl 44 (1970) 11-19
35. Stryjer R., Strous R.D., Bar F., Werber E., Shaked G., Buhiri Y., Kotler M., Weizman A., and Rabey J.M. Beneficial effects of donepezil augmentation for the management of comorbid schizophrenia and dementia. Clinical Neuropharmacology 26 (2003) 12-17
36. Tugal O., Yazici K.M., and Yagiociglu E.A. A double-blind, placebo controlled, cross-over trial of adjunctive donepezil for cognitive impairment in schizophrenia. International Journal of Neuropsychopharmacology 7 (2004) 117-123